| ID | 1307 |
| Name of the vaccine | Tritanrix-HepB/Hib |
| Microbe | Bacteria |
| Disease name | Tetanus (Lock Jaw) |
| Name of bacteria | Clostridium tetani |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 50 to 71 days |
| Description of the vaccine | Pentavalent combination vaccine. |
| Name of the manufacturer | Sanofi Pasteur, a Sanofi Company |
| Name of the manufacturing country | Mexico, Peru |
| Year of manufacture | 2008 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Gram-positive bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Three doses of 0.5 mL given at age 2, 4, and 6 months. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For diphtheria, tetanus, hepatitis B and haemophilus influenzae type b. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination (3 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT00313911 |
| Reference | https://www.vaccinebox.com/product/tritanrix-hb-hib/ |
| Other name | NA |
| Additional Links | NA
|